Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Exelixis Shares Climb 21% on Positive Phase 3 Advanced Kidney Cancer Study Results

Shares of Exelixis reached a new 52-week high price after the firm reported positive topline results from its Pivotal Phase 3 CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) in previously untreated advanced ...
Streetwise Reports | April 21, 2020 |

PDS Biotech Collaborating with Merck in Phase 2 Cancer Trial

This morning PDS Biotechnology Corp. shares are trading 38% higher after reporting that it will enter into a clinical collaboration with Merck pairing the firm's PDS0101 with KEYTRUDA for patients with recurrent or metastatic head and neck cancer and high-risk HPV16 infection....
Streetwise Reports | October 4, 2019 |

Genprex Shares Soar 250% on FDA Fast Track Designation for Lung Cancer Drug

Genprex's shares spiked 380% higher in morning trading as the company reported that the FDA granted Fast Track Designation for its Oncoprex immunogene therapy in combination with EGFR inhibitor osimertinib. This morning, Genprex Inc. (GNPX:NASDAQ) , which "utilizes a...
Streetwise Reports | January 22, 2020 |

Surface Oncology Shares Trade Up 40% on Phase1 Study Plans for SRF617 Combined with Merck's KEYTRUDA

Shares of Surface Oncology set a new 52-week high price after the company reported that it is partnering with Merck & Co. in an immuno-oncology study of SRF617, targeting CD39 in combination with KEYTRUDA® (pembrolizumab) in solid tumor patients. Clinical-...
Streetwise Reports | May 21, 2020 |

Mylan Gets a Shot in the Arm with Pfizer Merger Deal

EpiPen manufacturer Mylan N.V. announced today that the company will merge with Pfizer Inc.'s Upjohn Division, which holds Pfizer's off-patent branded and generic drugs, forming a new company. Mylan Inc. (MYL:NASDAQ) and Pfizer Inc. (PFE:NYSE) today anno...
Streetwise Reports | July 31, 2019 |

Immuno-Oncology Firm to Collaborate on Third Clinical Trial with Genentech

Descriptions of the new study and upcoming data readouts for this California-based firm were provided in an H.C. Wainwright & Co. report. In an April 29 research note, H.C. Wainwright & Co. analyst Swayampakula Ramakanth reported that Forty Seven Inc. (FTSV...
Streetwise Reports | May 2, 2019 |

Biotech's New Mesothelioma Trial Data Show Efficacy, Immunogenicity

These results of a study evaluating Targovax's lead candidate are reviewed and commented on in an H.C. Wainwright & Co. report. In a June 22 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Targovax ASA's (TRVX:OSE) ONCOS-102, in trial ...
Streetwise Reports | June 25, 2020 |

Myovant Sciences Shares Rise on NDA Filing for Uterine Fibroid Combination Therapy Drug

Shares of Myovant Sciences traded 40% higher after the company reported that it has submitted a New Drug Application to the FDA for once-daily relugolix combination tablet for the treatment of women with uterine fibroids. Healthcare company Myovant Sciences Ltd. (...
Streetwise Reports | June 2, 2020 |

ImmunoGen Shares Rise 25% on FY/19 Financial Results and Clinical Pipeline Updates

Shares of ImmunoGen Inc. reached a new 52-week intraday high price after the company announced FY/19 financial results and reported on recent developments including the completion of a $97.6 million capital raise in January 2020. Clinical-stage biotechnology...
Streetwise Reports | February 18, 2020 |

The Surging AR Company Leading the Industry

3D AR ads are coming to the market faster than you might think. Omri Wallach of Stockhouse Media was recently joined live on the line by Evan Gappelberg, CEO of NexTech AR Solutions ( CSE:NTAR , OTC:NEXCF , Forum ), fresh off the Company's recent re...
Omri Wallach | November 4, 2019 |
1 2 3 4 5 6 7 8 9 10 ...